Tandem Diabetes Care (TNDM) Cash from Investing Activities Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -100.09% |
| Dec 31, 2025 | 24.14% |
| Sep 30, 2025 | 16.53% |
| Jun 30, 2025 | 19.55% |
| Mar 31, 2025 | -22.53% |
| Dec 31, 2024 | 17.50% |
| Sep 30, 2024 | 2.14% |
| Jun 30, 2024 | 24.74% |
| Mar 31, 2024 | -53.42% |
| Dec 31, 2023 | -20.27% |
| Sep 30, 2023 | -0.72% |
| Jun 30, 2023 | 17.13% |
| Mar 31, 2023 | -22.58% |
| Dec 31, 2022 | 93.62% |
| Sep 30, 2022 | -125.30% |
| Jun 30, 2022 | 28.17% |
| Mar 31, 2022 | 14.79% |
| Dec 31, 2021 | -79.80% |
| Sep 30, 2021 | -54.23% |
| Jun 30, 2021 | -109.67% |
| Mar 31, 2021 | -30.08% |
| Dec 31, 2020 | -54.24% |
| Sep 30, 2020 | -69.41% |
| Jun 30, 2020 | -236.78% |
| Mar 31, 2020 | 30.61% |
| Dec 31, 2019 | -36.76% |
| Sep 30, 2019 | -7.92% |
| Jun 30, 2019 | -48.61% |
| Mar 31, 2019 | 15.16% |
| Dec 31, 2018 | -0.05% |
| Sep 30, 2018 | -78.08% |
| Jun 30, 2018 | -122.09% |
| Mar 31, 2018 | -46.68% |